J. Pawlotsky, Treatment of chronic hepatitis C: current and future, Curr Top Microbiol Immunol, vol.369, p.23463207, 2013.

T. Kanda, F. Imazeki, and O. Yokosuka, New antiviral therapies for chronic hepatitis C, Hepatol Int, vol.4, issue.3, p.21063477, 2010.
DOI : 10.1007/s12072-010-9193-3
URL : http://europepmc.org/articles/pmc2940000?pdf=render

A. Aghemo, D. Francesco, and R. , New horizons in hepatitis C antiviral therapy with direct-acting antivirals, Hepatology, vol.58, issue.1, p.23467911, 2013.

D. B. Smith, J. Bukh, C. Kuiken, A. S. Muerhoff, C. M. Rice et al., Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatol Baltim Md, vol.59, pp.318-345, 2014.

J. Pawlotsky, New hepatitis C therapies. Semin Liver Dis, vol.34, p.24782253, 2014.

, EASL Recommendations on Treatment of Hepatitis C, J Hepatol, vol.66, issue.1, p.27667367, 2016.

V. Cento, C. Mirabelli, R. Salpini, S. Dimonte, A. Artese et al., HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors, PLoS ONE, vol.7, issue.7, 2012.

B. Besse, M. Coste-burel, N. Bourgeois, C. Feray, B. Imbert-marcille et al., Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method, J Virol Methods, vol.185, issue.1, p.22728274, 2012.

K. Tamura, D. Peterson, N. Peterson, G. Stecher, M. Nei et al., MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods, Mol Biol Evol, vol.28, issue.10, p.21546353, 2011.

P. Kalaghatgi, A. M. Sikorski, E. Knops, D. Rupp, S. Sierra et al., A Webbased Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents, PloS One, vol.11, issue.5, p.27196673, 2016.

J. Pawlotsky, Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens, Gastroenterology, vol.151, issue.1, p.27080301, 2016.

C. Sarrazin, The importance of resistance to direct antiviral drugs in HCV infection in clinical practice, J Hepatol, vol.64, issue.2, p.26409317, 2016.

A. B. Jesudian, M. Gambarin-gelwan, and I. M. Jacobson, Advances in the treatment of hepatitis C virus infection, Gastroenterol Hepatol, vol.8, issue.2, pp.91-101, 2012.

F. Poordad and V. Khungar, Emerging therapeutic options in hepatitis C virus infection, Am J Manag Care, vol.17, issue.4, pp.123-130, 2011.

S. Larrat, S. Vallet, S. David-tchouda, A. Caporossi, J. Margier et al., Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin, J Clin Microbiol, vol.53, issue.7, p.25926499, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02014295

E. André-garnier, O. Ribeyrol, J. Gournay, B. Besse, M. Coste-burel et al., Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort, Antivir Ther, 2016.

S. Mansoor, A. Javed, A. Ali, and A. Mansoor, Heterogeneous genomic locations within NS3, NS4A and NS4B identified for genotyping and subtyping of Hepatitis C virus: A simple genome analysis approach, Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis, vol.44, pp.61-69, 2016.

K. S. Lole, J. A. Jha, S. P. Shrotri, B. N. Tandon, V. Prasad et al., Comparison of hepatitis C virus genotyping by 5' noncoding region-and core-based reverse transcriptase PCR assay with sequencing and use of the assay for determining subtype distribution in India, J Clin Microbiol, vol.41, issue.11, p.14605173, 2003.

S. Fourati and J. Pawlotsky, Virologic Tools for HCV Drug Resistance Testing, Viruses, vol.7, issue.12, pp.6346-59, 2015.

I. Jacobson, E. Asanthe-appiah, and P. Wong, Prevalence and impact of baseline NS5A resistance asoociated variants (RAVs) on the efficay of elbasvir/garzoprevir(EBR/GZR) against G1a infection (abst), Hepatology, vol.62, 2015.

D. R. Nelson, J. N. Cooper, J. P. Lalezari, E. Lawitz, P. J. Pockros et al., All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatol Baltim Md, vol.61, pp.1127-1162, 2015.

S. Zeuzem, R. Ghalib, K. R. Reddy, P. J. Pockros, B. Ari et al., Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial, Ann Intern Med, vol.163, issue.1, p.25909356, 2015.

G. R. Foster, N. Afdhal, S. K. Roberts, N. Bräu, E. J. Gane et al., Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection, N Engl J Med, vol.373, issue.27, pp.2608-2625, 2015.

M. P. Curry, J. G. O'leary, N. Bzowej, A. J. Muir, K. M. Korenblat et al., Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis, N Engl J Med, vol.373, issue.27, pp.2618-2646, 2015.

H. Dvory-sobol, D. Wyles, and W. Ouyang, Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir(abst), J Hepatol, vol.62, p.221, 2015.